HALO - Company ID 0001159036
The table below shows HALOZYME THERAPEUTICS, INC.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $133.82M | $115.85M | $118.37M | $234.19M | $118.72M | $147.70M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $426.27M | $288.20M | - | $231.07M | $90.97M | $97.73M |
| Inventory | $176.47M | $141.86M | $127.60M | $100.12M | $53.91M | $60.75M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $825.21M |
| $1.09B |
| $746.42M |
| $739.01M |
| $926.29M |
| $554.76M |
| Property, plant & equipment | $44.44M | $40.86M | $38.11M | $35.10M | $6.79M | $10.59M |
| Goodwill | $580.36M | $416.82M | $416.82M | $409.05M | - | - |
| Total assets | $2.53B | $2.06B | $1.73B | $1.84B | $1.10B | $579.92M |
| Accounts payable | $20.90M | $10.25M | $11.82M | $17.69M | $1.54M | $1.93M |
| Total current liabilities | $177.09M | $139.10M | $112.49M | $130.79M | $117.15M | $421.38M |
| Long-term debt | $2.14B | $1.51B | $1.50B | $1.49B | $787.25M | $0.00 |
| Total liabilities | $2.48B | $1.70B | $1.65B | - | - | - |
| Retained earnings | $54.79M | $359.87M | $90.55M | $143.22M | -$58.91M | -$474.59M |
| Total equity | $48.81M | $363.82M | $83.81M | $169.80M | $196.95M | $151.05M |